Media.Player

Novel Opiate Analogs for Therapeutic Applications

Detailed Technology Description

None

Supplementary Information

Inventor: Welsh, William J. | Yu, Seong Jae | Nair, Anil
Priority Number: US7164021B2
IPC Current: C07D047102 | A61P002504 | C07D047108 | C07D047110 | C07D047122 | C07D048908 | C07D049120 | C07D049122 | C07D049808
US Class: 546044 | 546045 | 546046
Assignee Applicant: The Curators of The University of Missourilumbia
Title: Opiate analogs selective for the delta-opioid receptor | Opiate analogs selective for the δ-opioid receptor
Usefulness: Opiate analogs selective for the delta-opioid receptor | Opiate analogs selective for the δ-opioid receptor
Summary: (I) are useful for the treatment of pain, protection of brain cells or in the decrease of gastric secretion. (I) are also useful for the treatment of transplant rejection diseases mediated by the δ-opioid receptor, preferably immune disorder, allergy, inflammation, drug or alcohol abuse, diarrhea, cardiovascular disease and respiratory disease (all claimed).
Novelty: New opiate derivatives, useful for the treatment of diseases mediated by delta opioid receptor e.g. immune disorder, cardiovascular disease and respiratory disease

Industry

Chemical/Material

Sub Category

Chemical/Material Application

Others

*Abstract

Researchers at the University of Missouri-St. Louis have designed novel compounds that selectively bind to the delta-opioid receptor. These compounds have greater selectivity, improved water/blood solubility, and enhanced therapeutic value as analgesics. Because they can provide enhanced pain-killing effects without addictive properties, these new compounds are better than delta-opioid receptor selectors, such as morphine, naltrindole (NTI) and spiroindanyloxymorphone (SIOM). The invention also provides a method for treating disease mediated by the delta-opioid receptor and a method for treating pain, decreasing gastric secretion, etc., using these novel compounds.Potential Applications-- Powerful, yet safe, analgesics for pain management-- Treatment of diseases and conditions mediated by the delta-opioid receptor, such as immune disorder, transplant rejection, allergy, inflammation, drug or alcohol abuse, diarrhea, cardiovascualr disease, and respiratory diseaseBenefits-- Powerful analgesics to treat pain without the negative side effects of narcotics such as morphine (e.g., addiction, respiratory depression, physical dependence, gastrointestinal problems, memory problems, insomnia, etc.)-- Compounds exhibit high binding affinity and high selectivity for the delta opioid receptors-- Compounds exhibit excellent water/blood solubility, allowing for oral administration of treatments

*Principal Investigator

Name: William Welsh

Department:

Name: Seong-Jae Yu

Department:

Name: Anil Nair, Senior Associate Scientist - Computational Chemistry

Department:

Country/Region

USA